Research Interests
cancer/oncogenesis
,
drugs/therapeutic agents pharm
Recent Publications
Aklilu M, Hussain A, Evans CP, Hannon RA, Lipton A, Dimairo M, Yu J, Zobel P, Torti FM, Finkelman RD.
A phase II, randomized, open-label, pilot study to evaluate the safety and the effects on bone resorption of saracatinib (AZD0530) in patients with prostate cancer or breast cancer with metastatic bone disease [abstract]. Bone.
2011;
48(1):S17.
Wong NS, Fernando NH, Nixon AB, Cushman S, Aklilu M, Bendell JC, Morse MA, Blobe GC, Ashton J, Pang H, et al.
A phase II study of capecitabine, oxaliplatin, bevacizumab and cetuximab in the treatment of metastatic colorectal cancer. Anticancer Res.
2011;
31(1):255-261.
Schaefer E, Aklilu M, Streer N, Schoppe K, Knovich MA.
Scurvy. Consultant.
2010;
50(3):135-136.
Finkelman RD, Aklilu M, Hannon RA, Hazzard E, Yu J, Zobel P.
Saracatinib (AZD0530) inhibits bone resorption in healthy volunteers and cancer patients [abstract]. Bone.
2010;
47(Suppl 2):S278-S279.
Monjazeb AM, Riedlinger G, Isom S, Aklilu M, Geisinger KR, Mishra G, Levine EA, Blackstock AW.
Radiotherapy for esophageal cancer: does dose affect outcomes? [abstract]. Int J Radiat Oncol Biol Phys.
2010;
78(3 Suppl):S307.
Petty WJ, Miller AA, Aklilu M, McCoy TP, Swift CB, Torti FM.
The tumor tissue renin-angiotensin system as a target for cancer therapy [abstract]. Int J Mol Med.
2010;
26(Suppl 1):S19.
Blackstock AW, Aklilu M, Lovato J, Degrass L, Sommer J, Howerton R, Mishra G, Levine E, McQuellon R.
Aprepitant/5HT-3 antagonist (EMEND) for the prevention of chemoradiation-induced nausea and vomiting (CRINV) in patients receiving gemcitabine/5-FU-based chemoradiation and concurrent upper abdominal radiation for pancreatic cancer [abstract]. J Clin Oncol.
2009;
27(Suppl):e20661.
Easler J, Fennimore B, Farmer M, Yacoub J, Geisinger K, Aklilu M, Blackstock W, Case D, Levine E, Mishra G.
Molecular profiling with MIB-1 correlates with microscopic evidence of residual disease in patients undergoing neoadjuvant therapy for esophageal cancer (EC) [abstract]. Gastroenterology.
2007;
132(4 Suppl 2):A854.
Kim C, Farmer MR, Yacoub J, Monjazeb A, Levine EA, Aklilu M, Geinsinger [sic] KR [Geisinger KR], Mishra G, Melin S, Blackstock AW.
Tri-modality therapy for esophageal cancer: mucinous histology is associated with decreased pathologic response rates to neoadjuvant chemoradiation therapy [abstract]. Int J Radiat Oncol Biol Phys.
2007;
69(3 Suppl):S267.
Farmer MR, Yacoub J, Aklilu M, Levine EA, Geisinger K, Mishra G, Melin S, Blackstock AW.
Tri-modality therapy for esophageal cancer: hemoglobin levels are prognostic for survival but do not predict response to radiochemotherapy [abstract]. Int J Radiat Oncol Biol Phys.
2006;
66(3 Suppl):S269.
All Publications
For a listing of recent publications, refer to PubMed, a service provided by the National Library of Medicine.
For a list of earlier publications, visit the Carpenter Library Publication Search.